AR and prostate carcinoma: Studies on androgen synthesis inhibitors (e.g., abiraterone) and androgen receptor antagonists (e.g., enzalutamide) have found that these forms of hormone therapy are increasing the incidence of androgen receptor negative (ARneg), androgen-independent (AI) prostate cancers [12–14].